Tidepath

Mitochondrial and metabolic compounds

MOTS-c

A peptide whose gene sits in your mitochondria, not in the cell nucleus.

Status
Not approved by the FDA.
Routes we have on file
By injection
Where doses come from
No checked dose range
Half-life
No measured half-life in people for native MOTS-c in our sources

What it is

MOTS-c is a short peptide whose gene sits in the DNA of mitochondria, the parts of a cell that make most of its energy, rather than in the cell's nucleus. The research we found on it centres on metabolism.

What makes it distinct

Tidepath shows no dose range for MOTS-c, on purpose. We found no studies in people that worked out a dose, and no named source for one that we could keep on file and check. So instead of a number nobody can trace, this page says there's no checked dose range.

Open questions

  • What dose, if any, has evidence behind it. We found no studies in people that worked out one.
  • CB4211, a drug modelled on MOTS-c, has been tested in people. It's a different molecule, so that research doesn't establish doses for MOTS-c itself or how long it lasts in the body.
  • How long it lasts in the body (pharmacokinetics). We found no measured half-life (the time it takes for half a dose to clear) in people. Tidepath doesn't chart its levels.

Worth knowing

The FDA says compounded MOTS-c (mixed from its ingredients by a pharmacist or doctor) given certain ways may carry a significant risk of immune reactions (immunogenicity). It also says it hasn't found any data on people taking drug products that contain it, by any route, and lacks important information on its safety, including whether it would harm people.

More in Mitochondrial and metabolic compounds